NURSE PROTOCOL FOR

Incyte exercised its option to co-develop Olumiant in rheumatoid arthritis in 2010 and psoriatic arthritis, atopic dermatitis, alopecia areata, and systemic lupus erythematosus in 2017. The. 17. agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. ................
................